Skip to content
2000
Volume 26, Issue 9
  • ISSN: 1389-2002
  • E-ISSN: 1875-5453

Abstract

Avacopan (Tavneos®) is approved as an oral adjunctive treatment at a dose of 30 mg twice daily with food for adult patients with severe active granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in combination with standard therapy including glucocorticoids.

Methods

In this pharmacokinetic (PK) study, the absorption, metabolism, and excretion of avacopan were evaluated following a single 100 mg/400 μCi oral 14C-avacopan dose solution in six healthy male participants. The mass balance recovery, plasma concentrations, and metabolite profile in plasma, urine, and feces were determined.

Results

Fecal and renal excretion accounted for 77.2% and 9.5%, respectively, of the total administered radioactivity, with none of the mono- or bis-oxidation metabolites present at greater than 7% of the total radioactive dose. In urine, intact avacopan was present at <1% of the radioactive dose. In feces, intact avacopan was present at 8.7%, which represented 6.7% of the total radioactive dose, suggesting at least 93.3% of the radioactive dose was absorbed. The predominant component in plasma was avacopan, which accounted for 18.0% of the dose. The major circulating metabolite, M1, a monohydroxylation metabolite with similar potency in C5a receptor inhibition as avacopan, accounted for 11.9% of the total radioactivity.

Discussion

The primary route of elimination of avacopan is phase I metabolism, followed by biliary excretion of the metabolites. CYP3A4 is the primary isozyme involved in the metabolism of avacopan and formation of metabolite M1.

Conclusion

Study results provide a definitive assessment of the absorption, elimination, and nature of metabolism of avacopan in humans.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdm/10.2174/0113892002370460251006055528
2025-10-10
2026-02-21

  • From This Site

    /content/journals/cdm/10.2174/0113892002370460251006055528
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Mechanism of Action.Available from: https://www.tavneospro.com/about-tavneos/moa.
  2. GargJ. FrishmanW.H. AVACOPAN: A new adjunctive therapy for antineutrophil cytoplasmic antibody-associated vasculitis.Cardiol. Rev.20233113610.1097/CRD.000000000000049636469359
     [Google Scholar]
  3. OsmanM. Cohen TervaertJ.W. PagnouxC. Avacopan for the treatment of ANCA-associated vasculitis.Expert Rev. Clin. Immunol.202117771772610.1080/1744666X.2021.193246634006155
     [Google Scholar]
  4. GabilanC. BelliereJ. MoranneO. PfirmannP. SamsonM. DelattreV. ThoreauB. GueutinV. BoyerA. LeursA. AstouatiQ. RonsinC. QuemeneurT. RibesD. KarrasA. FaguerS. Avacopan for anti-neutrophil cytoplasm antibodies-associated vasculitis: A multicentre real-world study.Rheumatology2024keae35910.1093/rheumatology/keae35939001799
     [Google Scholar]
  5. PeaseJ.E. Avacopan. C5a anaphylatoxin chemotactic receptor 1 (C5aR1) antagonist, Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.Drugs Future202146318310.1358/dof.2021.46.3.3239643
     [Google Scholar]
  6. TAVNEOS.2021Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214487 s000lbl.pdf.
  7. AlvarezL. KambhamN. SuR. Renal improvement and remission in a patient with refractory ANCA-associated vasculitis treated with avacopan.J. Nephrol.20233682365237010.1007/s40620‑023‑01614‑y37036661
     [Google Scholar]
  8. BekkerP. DairaghiD. SeitzL. LeletiM. WangY. ErtlL. BaumgartT. ShugartsS. LohrL. DangT. MiaoS. ZengY. FanP. ZhangP. JohnsonD. PowersJ. JaenJ. CharoI. SchallT.J. Characterization of pharmacologic and pharmacokinetic properties of ccx168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and Randomized Phase 1 Clinical Study. PLoS One, 2016, 11(10), e0164646.Correction: PLoS ONE2019141e021059310.1371/journal.pone.021059330608991
     [Google Scholar]
  9. JayneD.R.W. MerkelP.A. SchallT.J. BekkerP. Avacopan for the Treatment of ANCA-Associated Vasculitis.N. Engl. J. Med.2021384759960910.1056/NEJMoa202338633596356
     [Google Scholar]
  10. MiaoS. BekkerP. ArmasD. LorM. HanY. WebsterK. TrivediA. Pharmacokinetic evaluation of the cyp3a4 and cyp2c9 drug‐drug interaction of avacopan in 2 open‐label studies in healthy participants.Clin. Pharmacol. Drug Dev.202413551753310.1002/cpdd.138938423992
     [Google Scholar]
  11. KallenbergC.G.M. HeeringaP. Complement system activation in ANCA vasculitis: A translational success story?Mol. Immunol.2015681535610.1016/j.molimm.2015.06.00526597208
     [Google Scholar]
  12. XiaoH. DairaghiD.J. PowersJ.P. ErtlL.S. BaumgartT. WangY. SeitzL.C. PenfoldM.E.T. GanL. HuP. LuB. GerardN.P. GerardC. SchallT.J. JaenJ.C. FalkR.J. JennetteJ.C. C5a receptor (CD88) blockade protects against MPO-ANCA GN.J. Am. Soc. Nephrol.201425222523110.1681/ASN.201302014324179165
     [Google Scholar]
  13. MerkelP.A. JayneD.R. WangC. HillsonJ. BekkerP. Evaluation of the safety and efficacy of avacopan, a c5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody–associated vasculitis treated concomitantly with rituximab or cyclophosphamide/azathioprine: Protocol for a randomized, double-blind, active-controlled, phase 3 trial.JMIR Res. Protoc.202094e1666410.2196/1666432088663
     [Google Scholar]
  14. MiaoS. StaehrP. TaiE. DarpoB. XueH. ArmasD. WebsterK. OberoiR.K. A phase I thorough QT/QTc study evaluating therapeutic and supratherapeutic doses of avacopan in healthy participants.Clin. Transl. Sci.2024177e1387810.1111/cts.1387838973157
     [Google Scholar]
  15. MiaoS. BekkerP. ArmasD. LorM. HanadaR. OkamuraS. UmezawaY. TrivediA. Food Effect and Pharmacokinetic Bridging of Avacopan in Caucasian and Japanese Healthy Participants.Clin. Pharmacol. Drug Dev.20241391011102310.1002/cpdd.143638993035
     [Google Scholar]
  16. CoppolaP. AnderssonA. ColeS. The importance of the human mass balance study in regulatory submissions.CPT Pharmacometrics Syst. Pharmacol.201981179280410.1002/psp4.1246631515957
     [Google Scholar]
  17. Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies2024Available from: https://www.fda.gov/media/158178/download
  18. CernyM.A. SpracklinD.K. ObachR.S. Human absorption, distribution, metabolism, and excretion studies: Origins, innovations, and importance.Drug Metab. Dispos.202351664765610.1124/dmd.122.00100636973000
     [Google Scholar]
  19. HopC.E.C.A. WangZ. ChenQ. KweiG. Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening.J. Pharm. Sci.199887790190310.1021/js970486q9649361
     [Google Scholar]
  20. Safety Testing of Drug Metabolites - Guidance for Industry.2020Available from: www.fda.gov/media/72279/download.
  21. SchadtS. BisterB. ChowdhuryS.K. FunkC. HopC.E.C.A. HumphreysW.G. IgarashiF. JamesA.D. KaganM. KhojastehS.C. NeddermanA.N.R. PrakashC. RungeF. ScheibleH. SpracklinD.K. SwartP. TseS. YuanJ. ObachR.S. A decade in the mist: Learnings from investigations of drug metabolites in drug development under the “metabolites in safety testing” regulatory guidance.Drug Metab. Dispos.201846686587810.1124/dmd.117.07984829487142
     [Google Scholar]
  22. FDA Multi-Discipline Review.Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214487Orig1s000TOC.cfm
/content/journals/cdm/10.2174/0113892002370460251006055528
Loading
Mass Balance and Metabolic Profiling of Avacopan, a Selective C5a Receptor 1 Antagonist, in Healthy Humans
Current Drug Metabolism 26, 640 (2025); https://doi.org/10.2174/0113892002370460251006055528
/content/journals/cdm/10.2174/0113892002370460251006055528
/content/journals/cdm/10.2174/0113892002370460251006055528
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): AAV; ADME; avacopan; CYP3A4/3A5; GPA; metabolite; MPA

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test